Abingdon Health has significant experience developing and manufacturing rapid tests and readers in both regulated and non-regulated markets.
Abingdon Health was responsible for launching a lateral flow test for multiple myeloma (blood cancer), and led the UK Rapid Test Consortium in developing and manufacturing a COVID-19 rapid antibody test.
Whether working in regulated or non-regulated markets Abingdon Health’s adheres to the following quality management systems:
Visit our quality standards page to learn more about how Abingdon Health operates under ISO and GMP quality management systems.
As mentioned above, Abingdon Health led the development and manufacture of a rapid test that detects neutralising antibodies to SARS-CoV-2. The UK Government entered into a contract with Abingdon Health to use the rapid test, which is called AbC-19TM.
Read the AbC-19TM Whitepaper.
Also, read how Abingdon Health developed a rapid test for the quantification of kappa and lambda free light chains.